US20160002244A1

US20160002244A1 - Oxidated derivatives of triazolylpurines useful as ligands of the adenosine a2a receptor and their use as medicaments

Info

Publication number: US20160002244A1
Application number: US14/822,252
Authority: US
Inventors: Walter Cabri; Patrizia Minetti; Giovanni Piersanti; Giorgio Tarzia
Original assignee: Sigma Tau Industrie Farmaceutiche Riunite SpA
Current assignee: Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date: 2009-03-20
Filing date: 2015-08-10
Publication date: 2016-01-07
Also published as: JP5648044B2; ES2542555T3; HUE025704T2; JP2012520854A; TWI473809B; TW201100425A; EP2408775B1; HRP20150766T1; WO2010106145A1; US9133197B2; PT2408775E; AR075894A1; EP2408775A1; US20120053191A1; SI2408775T1; PL2408775T3; DK2408775T3; SMT201500174B

Abstract

The present invention relates to new triazolyl purine derivatives of formula (I), processes for their preparation, and to pharmaceutical compositions containing them for the treatment of neurological disorders or cerebral ischaemia for which inhibition of adenosine A2A receptor will result at improving the health state of a patient.

Description

RELATED APPLICATIONS AND INCORPORATION BY REFERENCE

This application is a Divisional of U.S. application Ser. No. 13/257,750 filed Nov. 14, 2011, which is a National Stage Entry of PCT/EP2010/053554 filed Mar. 18, 2010, which published as PCT Publication No. WO 2010/106145 on Sep. 23, 2010, which claims benefit of European Patent Application EP 09155690.2 filed Mar. 20, 2009.
The foregoing applications, and all documents cited therein or during their prosecution (“appin cited documents”) and all documents cited or referenced in the appin cited documents, and all documents cited or referenced herein (“herein cited documents”), and all documents cited or referenced in herein cited documents, together with any manufacturer's instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein, are hereby incorporated herein by reference, and may be employed in the practice of the invention. More specifically, all referenced documents are incorporated by reference to the same extent as if each individual document was specifically and individually indicated to be incorporated by reference.

FIELD OF THE INVENTION

The present invention relates to new triazolyl purine derivatives, processes for their preparation, and to pharmaceutical compositions containing them for the treatment of neurological disorders for which inhibition of adenosine A_2Areceptor will result at improving the health state of a patient.

BACKGROUND OF THE INVENTION

Adenosine A₂is an endogenous modulator, which among other effects mediates a general depression of the central nervous system, vasodilatation and inhibition of platelet aggregation.
Adenosine receptors represent a subclass (P1) of the group of purine nucleotide and nucleoside receptors known as purinoreceptors. Up to now, four subtypes of adenosine receptors are known (i.e., A₁, A_2A, A_2B(of high and low affinity) and A₃receptors). Adenosine receptors are all coupled to G-proteins; A₁and A₃subtypes are associated with inhibitory G-proteins and the A_2Aand A_2Bsubtypes are associated with stimulatory G-proteins. Activation of the A₁and A₃receptors causes inhibition of adenylate cyclase and phospholipase C, which inhibits neurotransmission. The A₁receptors are highly expressed in the brain, especially in the hippocampus, thalamus, cerebellum and cortex compared to the A₃receptors which are moderately expressed in the brain. Activation of the A_2Aand A_2Breceptors causes activation of adenylate cyclase and phospholipase C, resulting in the stimulation of neurotransmission. A_2Areceptors are co-expressed in the brain with dopamine D2 receptors, especially in the striatum, olfactory tubercle and nucleus accumbens and are involved in neurodegenerative pathologies.
A_2areceptors are densely distributed in the central nervous system (striatum, nucleus accumbens and olfactory tubercles) where they play an important role in the regulation of mood and motor activity (Poulsen, S. A., et al., Bioorg. Med. Chem., 1998, 6, 619; Ongini, E., et al., Trends Pharmacol. Sci., 1996, 17, 364). Parkinson's disease has been treated for more than thirty years by dopamine replacement strategies (Cotzias, G. C., et al., N. Engl. J. Med., 1969, 280, 337). However, because long-term use of dopamine-replacing agents is associated with severely disabling side effects, most notably dyskinesia (Chase T. N., Neurology, 1998, 50, S17-S25), non-dopaminergic treatments as monotherapies were judged as a promising strategy to treat such a disease (Brotchie, J. M., Curr. Opin. Neurol., 1997, 10, 340). Moreover, some scientific evidences also suggest that increased synthesis of adenosine A_2areceptors in striatopallidal pathway neurons is associated with the development of dyskinesias following long-term levodopa therapy in Parkinson's disease (Calon, F., et al., Brain, 2004, 127, 1075; Xiao, D., et al., J. Neurosci., 2006, 26, 52, 13548). A_2Aantagonists, in association with a low dose of L-DOPA, displayed antiparkinsonian activity similar to that produced by a full dose of L-DOPA without exacerbating abnormal motor side effects (Tronci E., et al. Eur J. Pharmacol., 2007, 566, 94; Jenner P., Expert Opin. Investig. Drugs, 2005, 14, 6, 729).
Adenosine has also been implicated in numerous other pathologies such as epilepsy, cerebral ischaemic preconditioning, sleep and immune reaction within the brain (Brundege, J. M., et al., Adv. Pharma., 1997, 39, 353).
Imidazopyrimidine derivatives of formula A as antidiabetic compounds are disclosed in U.S. Pat. No. RE39112 E (Eisai Co., Ltd.).
94% of the latter compounds (223 out of 237 exemplified compounds) present a fluoro-containing phenyl moiety as R³group and/or a tertiary alcohol within the R¹radical, suggesting that those moieties constitute an important feature to confer the activity.
A patent (EP1412354) filed by the Applicant disclosed triazolylimidazopyridine and triazolylpurine derivatives endowed of anti-psychotic properties. However, none of the compounds of the present invention were neither disclosed nor suggested.

DESCRIPTION OF THE INVENTION

The invention provides novel compounds of formula I, or a hydrate or solvate thereof and compositions that include such compounds endowed with adenosine A_2ainhibiting properties:

- R¹═ is C₁-C₆linear or branched alkyl;
- R²is a group of formula R⁹—(CHR⁸)_p—(CR⁶R⁷)_m—(CR⁴R⁵)_n—;
- R⁴, R⁶and R⁸are at any occurrence independently H, hydroxyl or ═O with the meaning of carbonyl;
- R⁵, R⁷and R⁹are at any occurrence independently H or are absent;
- m, n and p are independently an integer comprised between 0 and 2;
- m+n+p≧4;
- R³is NH₂, NHR¹⁰;
- r¹⁰is C₁-C₆alkyl or C₁-C₆hydroxyalkyl, C₁-C₃alkoxyalkyl, amino(C₁-C₆)alkyl, where the amino group is optionally substituted with one or two C₁-C₃alkyl groups, being said alkyl groups linear or branched; C₆-C₁₄aryl or C₆-C₁₄aryl(C₁-C₆)alkyl, with the aryl group optionally substituted by one or more substituents, either the same or different, selected from the group constituted by halogen, hydroxy, C₁-C₆alkoxy linear or branched saturated or unsaturated, amino, mono- or di-substituted with C₁-C₆alkyl linear or branched;
- their optically active forms such as enantiomers, diastereomers and their racemate forms, and pharmaceutically acceptable salts thereof; with the proviso that R⁴, R⁶and R⁸are not all H at the same time.

We have found that the derivatives (I), prepared according to the invention, are useful agents for the treatment of disease states, disorders and pathological conditions wherein modulation of the A_2Areceptor activity would result at improving the health of the patient.
An embodiment of this invention is that of compounds of formula I, for use as medicaments.
In another embodiment, said medicament is used for treating a subject affected by motor disorders deriving from functional alterations in the basal ganglia.
In a still further embodiment, said motor disorders consist of the ones involved in diseases comprising Parkinson's disease, Alzheimer's disease, Huntington's disease and Wilson's disease.
In another embodiment, the compounds of formula I are also useful for the preparation of medicaments for the treatment of cerebral ischaemia and/or associated with neurodegenerative processes.
The term “alkyl” refers to linear or branched alkyl groups having from 1 to 6 carbon atoms. Preferred alkyl groups are exemplified by groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, neo-butyl, tert-butyl, pentyl, iso-pentyl, n-hexyl and the like.
The term “alkenyl” refers to linear or branched alkenyl groups preferably having from 2 to 12 carbon atoms, or preferably, 2 to 6 carbon atoms also named “lower” alkenyl group and having at least 1 or 2 sites of alkenyl unsaturation. Preferable alkenyl groups include ethenyl (—CH═CH2), propenyl (allyl, —CH₂CH═CH₂) and the like. The term alkenyl embraces radicals having “cis” and “trans” orientation, or alternatively “Z” and “E”.
The term “cycloalkyl” refers to a saturated or partially unsaturated (i.e., not aromatic) carbocyclic group of from 3 to 10 carbon atoms having a single ring or multiple condensed rings.
Examples of C₃-C₁₀cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornyl, adamantyl and the like.
The term “heterocycloalkyl” refers to a saturated or partially unsaturated (i.e., not aromatic) five-, six- or seven-membered ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen or sulfur atoms, and which rings may be substituted with lower alkyl, lower alkenyl, or aryl. Preferred heterocycloalkyl include pyrrolidine, piperidine, piperazine, ketopiperazine, thiomorpholine, 2,5-diketopiprazine, 1-methylpiperazine, morpholine, dihydropyranyl, tetrahydropyranyl, tetrahydrofuran, dihydropyrrole, imidazolidine, dihydropyrazole, pyrazolidine and the like.
The term “aryl” refers to an aromatic carbocyclic group of 6 to 14 carbon atoms having a single ring (e. g., phenyl) or multiple rings that may be attached in a pendent manner or may be fused. Preferred aryl include phenyl.
The term “alkoxy” refers to the group —O—R where R includes “C₁-C₆alkyl”, “C₂-C₆alkenyl”, “C₃-C₁₀cycloalkyl” and “heterocycloalkyl”.
The term “alkoxyalkyl” refers to alkyl groups as above defined having an alkoxy substituent as above defined, including 2-ethoxyethyl, methoxymethyl and the like.
The term “amino” refers to the group —NRR′ where each R, R′ is independently H, “alkyl”, “alkenyf”, “cycloalkyl”, “heterocycloalkyl”, “aryl”, “heteroaryl” and where R and R′, together with the nitrogen atom to which they are attached, can optionally form a 3 to 8-membered heterocycloalkyl ring as above defined. The term “aminoalkyl” or “amino(C₁-C₆)alkyl” refers to alkyl groups as above defined having an amino substituent as above defined.
“Pharmaceutically acceptable salts or complexes” refers to salts or complexes of the below identified compounds of formula (I), that retain the desired biological activity. Examples of such salts include, but are not restricted to acid addition salts formed with inorganic acids (e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like), and salts formed with organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, fumaric acid, maleic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphthalene sulfonic acid, toluene sulfonic acid, naphthalene disulfonic acid, methanesulfonic acid and poly-galacturonic acid. When the salt is of a mono acid (for example, the hydrochloride, the hydrobromide, the p-toluenesulphonate, or the acetate), the hydrogen form of a di-acid (for example, the hydrogen sulphate, or the succinate), or the dihydrogen form of a tri-acid (for example, the dihydrogen phosphate, or the citrate), at least one molar equivalent and usually a molar excess of the acid is employed. However, when such salts as the sulphate, the hemisuccinate, the hydrogen phosphate, or the phosphate are desired, the appropriate and exact chemical equivalents of acid are generally used.
“Pharmaceutically active derivative” refers to any compound that upon administration to the patient is capable of providing directly or indirectly, the activity disclosed herein.
The compounds according to formula I could be employed alone or in combination with further pharmaceutical agents such as L-DOPA.
The compounds of the present invention may be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred experimental conditions (i.e., reaction temperatures, time, moles of reagents, solvents, etc.) are given, other experimental conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by one skilled in the art by routine optimisation procedures.
When employed as pharmaceuticals, the compounds of the present invention are typically administered in the form of a pharmaceutical composition. Hence, pharmaceutical compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, diluent or excipient therefore is also within the scope of the present invention. Such compositions can be prepared in a manner well known in the pharmaceutical art and comprise at least one active compound. A person skilled in the art is aware of a whole variety of such carrier, diluent or excipient compounds suitable to formulate a pharmaceutical composition.
The compounds of the present invention, together with a conventionally employed adjuvant, carrier, diluent or excipient may be placed into the form of pharmaceutical compositions and unit dosages thereof, and such forms may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, or in the form of sterile injectable solutions for parenteral (including subcutaneous use). Such pharmaceutical compositions and unit dosage forms thereof may comprise ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
Generally, the compounds of this invention are administered in a “pharmaceutically effective amount”. The amount of the compound actually administered will typically be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, drug combination, the age, body weight, and response of the individual patient, the severity of the patient's symptoms, and the like. Generally, an effective dose will be from 0.01 mg/kg to 100 mg/kg, preferably 0.05 mg/kg to 50 mg/kg. Compositions may be administered individually to a patient or may be administered in combination with other agents, drugs or hormones. For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays or in animal models, usually mice, rats, guinea pigs, rabbits, dogs, or pigs.
The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans. In calculating the Human Equivalent Dose (HED) it is recommended to use the conversion table provided by the FDA in Guidance for Industry and Reviewers document available from FDA. The pharmaceutical compositions of this invention can be administered by a variety of routes including oral, rectal, sublingual, transdermal, subcutaneous, intravenous, intramuscular, intrathecal, intraperitoneal, intranasal and locally on the diseased tissue after surgical operation.
Depending on the intended route of delivery, the compounds are preferably formulated as parenteral, topical or oral compositions. The compositions for oral administration may take the form of bulk liquid solutions or suspensions, or bulk powders. More commonly, however, the compositions are presented in unit dosage forms to facilitate accurate dosing. The term “unit dosage forms” refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient. Typical unit dosage forms include refilled, pre-measured ampoules or syringes of the liquid compositions or pills, tablets, capsules or the like in the case of solid compositions. In such compositions, the compound of the invention is usually a minor component (from about 0.1 to about 50% by weight or preferably from about 1 to about 40% by weight) with the remainder being various vehicles or carriers and processing aids helpful for forming the desired dosing form.
Dosage treatment may be a single dose schedule or a multiple dose schedule. Liquid forms suitable for oral administration may include a suitable aqueous or non-aqueous vehicle with buffers, suspending and dispensing agents, colorants, flavours and the like.
Solid forms may include, for example, any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, acacia, gum tragacanth, gelatine or polyvinyl-pyrrolidone; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, primogel, or potato or corn starch; a lubricant such as magnesium stearate, talc, polyethylene glycol or silica; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring. The tablets may be coated according to methods well known to people skilled in the art of pharmaceutical practice.
Parenteral compositions are typically based upon injectable sterile saline or phosphate-buffered saline or other injectable earners known in the art. As mentioned above, the compound of formula I in such compositions is typically a minor component, frequently ranging between 0.05 to 10% by weight with the remainder being the injectable carrier and the like.
The compounds of this invention can also be administered in sustained release forms or from sustained release drug delivery systems. A description of representative sustained release materials can also be found in the incorporated materials in Remington's Pharmaceutical Sciences.
The above-described components for orally administered or parenteral compositions are merely representative. Further materials as well as processing techniques and the like are set out in Part 5 of Remington's Pharmaceutical Sciences, 20th Edition, 2000, Mack Publishing Company, Easton, Pa., which is incorporated herein be reference.
A further embodiment of the invention is a process for the preparation of pharmaceutical compositions characterised by mixing one or more compounds of formula (I) with suitable excipients, stabilizers and/or pharmaceutically acceptable diluents.
As above disclosed, the compounds of the present invention are useful as medicaments due to their Aza modulating properties for the treatment of disorders where such modulation result in improving the health of the patient. In particular, patients suffering from Parkinson's disease, Alzheimer's disease, Huntington's disease, Wilson's disease, psychiatric disorders, Hallervorden-Spatz disease, progressive pallidal atrophy and diabetes can be treated.
Objects of the present invention are pharmaceutical compositions containing compounds of formula I, as described earlier, in combination with excipients and/or pharmacologically acceptable diluents.
A further embodiment of the invention is a process for the preparation of compounds of formula I as defined above. The compounds of the invention can be prepared by conventional synthetic methods and are described underneath.

Method A

Compounds of formula (I), wherein

- R¹═ is C₁-C₆linear or branched alkyl;
- R₂is a group of formula R⁹—(CHR⁸)_p—(CR⁶R⁷)_m—(CR⁴R⁵)_n—;
- R⁴, R⁵, R⁷, and R⁹are H;
- R⁶and R⁸are at any occurrence independently H or hydroxyl with at least one of them being hydroxyl;
- m and p are independently an integer comprised between 0 and 2;
- n is 1 or 2;
- m+n+p≧4;
- R³is NH₂, NHR¹⁰; and
- R¹⁰is C₁-C₆alkyl or C₁-C₆hydroxyalkyl, C₁-C₃alkoxyalkyl, amino(C₁-C₆)alkyl, where the amino group is optionally substituted with one or two C₁-C₃alkyl groups, being said alkyl groups linear or branched; C₆-C₁₄aryl or C₆-C₁₄aryl(C₁-C₆)alkyl, with the aryl group optionally substituted by one or more substituents, either the same or different, selected from the group constituted by halogen, hydroxy, C₁-C₆alkoxy linear or branched saturated or unsaturated, amino, mono- or di-substituted with C₁-C₆alkyl linear or branched;
- can be synthesized by a process comprising the reaction of a compound of formula II

- wherein
- R¹is C₁-C₆linear or branched alkyl;
- R^His N(R¹³)₂;
- R¹³is benzyl, p-(MeO)-benzyl, p-(Cl)-benzyl or p-(Br)-benzyl;
- R¹²is Cl;
- with a compound of formula III

R⁹—(CHR^8a)_p—(CR^6aR⁷)_m—(CR⁴R⁵)_n—MgX Formula III,

- wherein,
- X is Cl or Br;
- R⁴, R⁵, R⁷, and R⁹are H;
- R^6aand R^8aare at any occurrence independently OH or H with at least one of them being OH;
- m and pare independently an integer comprised between 0 and 2;

n is 1 or 2;

- m+n+p≧4;
- in the presence of Fe(acac)₃in an aprotic solvent such as THF or NMP at a temperature ranging from 0° C. to RT.

Method B

Compounds of formula (I), wherein

- R¹is C₁-C₆linear or branched alkyl;
- R²is a group of formula R⁹—(CHR⁸)_p—(CR⁶R⁷)_m—(CR⁴R⁵)_n—;
- R⁴and R⁵are H;
- R⁶and R⁸are at any occurrence independently H or ═O with the meaning of carbonyl; with at least one of R⁶and R⁸being ═O with the meaning of carbonyl;
- R⁷and R⁹are at any occurrence independently H, or are absent in case the corresponding carbon atom bearing said R⁶or R⁸group is involved in a carbonyl bond;
- m and p are independently an integer comprised between 0 and 2;
- n is 1 or 2;
- m+n+p≧4;
- R³is NH₂, NHR¹⁰;
- R¹⁰is C₁-C₆alkyl or C₁-C₆hydroxyalkyl, C₁-C₃alkoxyalkyl, amino(C₁-C₆)alkyl, where the amino group is optionally substituted with one or two C₁-C₃alkyl groups, being said alkyl groups linear or branched; C₆-C₁₄aryl or C₆-C₁₄aryl(C₁-C₅)alkyl, with the aryl group optionally substituted by one or more substituents, either the same or different, selected from the group constituted by halogen, hydroxy, C₁-C₆alkoxy linear or branched saturated or unsaturated, amino, mono- or di-substituted with C₁-C₆alkyl linear or branched;
- can be synthesized by a process comprising the reaction of a compound of formula II as defined above, with a compound of formula IV

H—(CH₂)_q—(CR^6bR^6c)_r—(CH₂)_s—MgX Formula IV,

- wherein
- X is C¹or Br;
- R^6band R^6care at any occurrence independently both H or when taken together with the carbon atom to which they are attached to form a 1,3-dioxane group optionally substituted by two or more methyl groups with at least one of the occurrence being a 1,3-dioxane group substituted by two or more methyl groups;
- q is an integer comprised between 0 and 3;
- r and s are independently an integer comprised between 1 and 3; with q+r+s≧4; in the presence of a Fe(acac)₃in an aprotic solvent such as THF or NMP at a temperature ranging from 0° C. to RT.

Method C

Compounds of formula (I), wherein

- R¹is C¹-C⁶linear or branched alkyl;
- R²is a group of formula R⁹—(CHR⁸)_p—(CR⁶R⁷)_m—(CR⁴R⁵)_n;
- R⁴is hydroxyl or ═O with the meaning of carbonyl;
- R⁵is H or is absent when R⁴is =) with the meaning of carbonyl;
- R⁶and R⁸are at any occurrence independently H, hydroxyl or ═O with the meaning of carbonyl;
- R⁷and R⁹are at any occurrence independently H or are absent in case the corresponding carbon atom bearing said R⁶or R⁸group is involved in a carbonyl bond;
- n is 1;
- m and p are independently an integer comprised between 1 and 2, with m+p≧3;
- R¹⁰is C₁-C₆alkyl or C₁-C₆hydroxyalkyl, C₁-C₃alkoxyalkyl, amino(C₁-C₆)alkyl, where the amino group is optionally substituted with one or two C₁-C₃alkyl groups, being said alkyl groups linear or branched; C₆-C₁₄aryl or C₆-C₁₄aryl(C₁-C₆)alkyl, with the aryl group optionally substituted by one or more substituents, either the same or different, selected from the group constituted by halogen, hydroxy, C₁-C₆alkoxy linear or branched saturated or unsaturated, amino, mono- or di-substituted with C₁-C₆alkyl linear or branched;
- can be synthesized by a process comprising the following steps:
  - a) reaction of a compound of formula V

- wherein R¹is C₁-C₆linear or branched alkyl;
- with i-PrMgCl;
  - b) in situ addition of compound formula VI

H—(CHR^8d)_t—(CR^6dR^7d)_s—CHO Formula VI

- wherein:
- R^6dand R^7dare at any occurrence independently H or OH with at least one of them being H; or
- R^6dand R^7dwhen taken together with the carbon atom to which they are attached, form a 1,3-dioxane group optionally substituted by two or more methyl groups;
- R^8dis H or hydroxyl;
- s and t are independently an integer comprised between 1 and 2, with s+t≧3;
- in an aprotic solvent such as THF at a temperature ranging from −78° C. to RT.

Method D

Compounds of formula (I), wherein

- R¹═ is C₁-C₆linear or branched alkyl;
- R₂is a group of formula R⁹—(CHR⁸)_p—(CR⁶R⁷)_m—(CR⁴R⁵)_n—;
- R⁴and R⁵are H;
- R⁶and R⁸are at any occurrence independently H, hydroxyl or ═O with the meaning of carbonyl;
- R⁷and R⁹are at any occurrence independently H or are absent in case the corresponding carbon atom bearing said R⁶or R⁸group is involved in a carbonyl bond;
- m and p are independently an integer comprised between 0 and 2;
- n=2;
- m+n+p≧4;
- R³is NH₂, NHR¹⁰;
- R¹⁰is C₁-C₆alkyl or C₁-C₆hydroxyalkyl, C₁-C₃alkoxyalkyl, amino(C₁-C₆)alkyl, where the amino group is optionally substituted with one or two C₁-C₃alkyl groups, being said alkyl groups linear or branched; C₆-C₁₄aryl or C₆-C₁₄aryl(C₁-C₆)alkyl, with the aryl group optionally substituted by one or more substituents, either the same or different, selected from the group constituted by halogen, hydroxy, C₁-C₆alkoxy linear or branched saturated or unsaturated, amino, mono- or di-substituted with C₁-C₆alkyl linear or branched;
- can be synthesized by a process comprising the reaction of a compound of formula VII

- wherein
- R¹═ is C₁-C₆linear or branched alkyl; with a compound of formula VIII

- wherein
- R⁶is at any occurrence independently H or hydroxyl,
- u is an integer equal to or greater than 2;
- in the presence of bis-triphenylphosphine palladium dichloride, CuI and optionally a tertiary amine such as triethylamine in a polar solvent such as dioxane at a temperature ranging from 0° C. to RT.

Method E

Compounds of formula (I), wherein

- R¹═ is C₁-C₆linear or branched alkyl;
- R²is a group of formula R⁹—(CHR⁸)_p—(CR⁶R⁷)_m—(CR⁴R⁵)_n—;
- R⁴, R⁶and R⁸are at any occurrence independently H, hydroxyl or ═O with the meaning of carbonyl;
- R⁵, R⁷and R⁹are at any occurrence independently H or are absent in case the corresponding carbon atom bearing said R⁴, R⁶or R⁸group is involved in a carbonyl bond;
- m, n and p are independently an integer comprised between 0 and 2;
- m+n+p≧4;
- R³is NH₂, NHR10;
- R¹⁰is C₁-C₆alkyl or C₁-C₆hydroxyalkyl, C₁-C₃alkoxyalkyl, amino(C₁-C₆) alkyl, where the amino group is optionally substituted with one or two C₁-C₃alkyl groups, being said alkyl groups linear or branched; C₆-C₁₄aryl or C₆-C₁₄aryl(C₁-C₆)alkyl, with the aryl group optionally substituted by one or more substituents, either the same or different, selected from the group constituted by halogen, hydroxy, C₁-C₆alkoxy linear or branched saturated or unsaturated, amino, mono- or di-substituted with C₁-C₆alkyl linear or branched;
- can be synthesized by a process comprising the reaction of compounds of formula II as above described with a compound of formula IX

- wherein
- R¹⁴is at each occurrence independently H or OH;
- R¹⁵is H or OH;

v is ≧2;

- in the presence of Hermann's catalyst and sodium acetate in a polar solvent such as NMP.

Method F

Compounds of formula (I), wherein

- R¹═ is C₁-C₆linear or branched alkyl;
- R2 is a group of formula R⁹—(CHR⁸)_p—(CR⁶R⁷)_m—(CR⁴R⁵)_n—;
- R⁴and R⁵are H;
- R⁶and R⁸are at any occurrence independently H, hydroxyl or ═O with the meaning of carbonyl;
- R⁷and R⁹are at any occurrence independently H or are absent;
- m and p are independently an integer comprised between 0 and 2;
- n≧1;
- m+n+p≧4;
- R³is NH₂, NHR¹⁰;
- R¹⁰is C₁-C₆alkyl or C₁-C₆hydroxyalkyl, C₁-C₃alkoxyalkyl, amino(C₁-C₆)alkyl, where the amino group is optionally substituted with one or two C₁-C₃alkyl groups, being said alkyl groups linear or branched; C₆-C₁₄aryl or C₆-C₁₄
- aryl(C₁-C₆)alkyl, with the aryl group optionally substituted by one or more substituents, either the same or different, selected from the group constituted by halogen, hydroxy, C₁-C₆alkoxy linear or branched saturated or unsaturated, amino, mono- or di-substituted with C₁-C₆alkyl linear or branched;
- can be synthesized by a process comprising the reaction of compounds of formula VII as above described with a compound of formula X

R⁹—(CHR⁸)_p—(CR^6dR^7d)_m—(CR⁴R⁵)_n—ZnBr Formula X;
wherein

- R⁴and R⁵are H;
- R^6dand R^7dare at any occurrence independently H or OH with at least one of them being H; or
- R^6dand R^7dwhen taken together with the carbon atom to which they are attached, form a 1,3-dioxane group optionally substituted by two or more methyl groups;
- R⁸is at any occurrence independently H or hydroxyl;
- R⁹is H;
- m and p are independently an integer comprised between 0 and 2;
- n≧1;
- m+n+p≧4;
- in a polar solvent such as THF.

In all said transformations, any interfering reactive group can be protected and then deprotected according to well-established procedures described in organic chemistry (see for example: Greene T. W. and P. G. M. Wuts “Protective Groups in Organic Synthesis”, J. Wiley & Sons, Inc., 3rd Ed., 1999) and well known to those skilled in the art.

DESCRIPTION OF THE DRAWING

FIG. 1: it shows the efficacy of ST3932 at antagonizing the haloperidol-induced catalepsy in mice.

FIG. 2: it shows the efficacy of ST4206 at increasing the number of 5 contralateral rotation of 6-OHDA lesioned rats.

FIG. 3: it shows the efficacy of ST3829 at increasing the number of contralateral rotation of 6-OHDA lesioned rats.

FIG. 4: it shows the efficacy of ST3932 at increasing the number of contralateral rotation of 6-OHDA lesioned rats.

FIG. 5: it shows the efficacy of ST4206 at increasing the number of contralateral rotation of 6-OHDA lesioned rats.

EXAMPLES

Abbreviations

AcOEt: ethyl acetate
atm: atmosphere
bs: broad singlet
DCM: dichloromethane
DMEM: Dulbecco's modified eagle's medium
DMSO: dimethylsyulfoxide
EDTA: ethylenediaminetetraacetic acid
Et₂O: diethyl ether
FBS: foetal Bovine Serum
MeOH: methanol
MgCl₂: magnesium dichloride
MS: mass spectrum
Na₂SO₄: sodium sulphate
NEt_a: triethyl amine
NMP: N-methyl pyrrolidinone
PBS: phosphate-buffered saline
PCC: pyridinium chlorochromate
RP-HPLC: reversed phase-high-performance liquid chromatography
Rt: retention time
RT: room temperature
TfOH: Trifluoromethanesulfonic acid
General Remarks: ¹H spectra were recorded in CDCl₃or DMSO-d₆solution as indicated, at 200 MHz with a Bruker instrument. The chemical shift values are given in ppm and the coupling constants in Hz. Flash column chromatography was carried out using silica gel (Merck 230-400 mesh).
Chiral chromatography was performed using a HPLC Shimadzu LC-10AS chromatograph connected with a Vis-UV SPD 10A Shimadzu detector and a Shimadzu C-R6A chromatopak integrator. The stationary phase consisted of a Chiralpak AD-H column, Daicel Chemical industries (Chiral France) [Amylose tris(3,5-dimethylphenylcarbamate) coated on 5 mm silica-gel] of diameter 0.46 cm, length 25 cm. The mobile phase consisted of n-hexane/2-propanol: 9/1 at a flow equal to 1 ml/min, λ289 nm.

Example 1

4-(6-Amino-9-methyl-8 [1,2,3]triazol-2-yl-9H-purin-2-yl)butan-1-ol (ST4023)

STEP A: 4-(6-Chloro-9-methyl-9H-purin-2-yl)but-3-yn-1-ol

NEt₃(4.9 ml, 34.5 mmol) and but-3-yn-1-ol (1.1 ml, 25.63 mmol) were added to a solution of 6-chloro-2-iodo-9-methyl-9H-purine (6.8 g, 23.3 mmol), CuI (454 mg, 2.23 mmol) and bis-triphenylphosphine palladium dichloride (811 mg, 1.15 mmol) in dioxane (93 ml). The reaction mixture was stirred at RT for 1 h. The solvents were removed under reduced pressure. Water (50 ml) was added to the dark residue obtained. The aqueous phase was extracted with DCM (3×100 ml). The combined organic phases were dried over anhydrous sodium sulphate and evaporated under reduced pressure. The residue was purified by flash chromatography (DCM/MeOH: 94/6) to give an off-white precipitate.
Yield 77%.
¹H NMR (DMSO-d₆) δ: 2.67 (t, 2H, J=6.82 Hz), 3.68 (t, 2H, J=6.82 Hz), 3.86 (s, 3H), 5.01 (bs, 1H), 8.68 (s, 1H).
¹³C NMR (DMSO-d₆) δ: 23.33, 30.63, 59.62, 80.55, 88.11, 130.42, 144.73, 148.86, 149.28, 152.79
MS(ESI) m/e: 237-239 (M+H)+

STEP B: 4-(6-Amino-9-methyl-9H-purin-2-yl)but-3-yn-1-ol

To a solution of 4-(6-chloro-9-methyl-9H-purin-2-yl)but-3-yn-1-ol (650 mg, 2.74 mmol) in dioxane (4 ml) was added 30% w/w water solution of ammonia (8 ml). The reaction mixture was stirred overnight in an autoclave at 70° C.
The solution was evaporated at atmospheric pressure at 50° C. to remove the ammonia. The reaction mixture was maintained at RT for 2 h, to give a white precipitate. The solid was filtered and dried under vacuum.
Yield 78%.
¹H NMR (DMSO-d₆) δ: 2.52 (t, 2H, J=6.82 Hz), 3.58 (dt, 2H, J=6.82 Hz, J=5.5 Hz), 3.68 (s, 3H), 4.90 (t, 1H, J=5.5 Hz), 7.25 (bs, 2H), 8.09 (s, 1H).
¹³C NMR (DMSO-d₆) δ: 23.24, 29.84, 59.95, 82.23, 83.46, 118.51, 142.58, 146.01, 150.38, 156.05
MS(ESI) m/e: 218 (M+H)⁺

STEP C: 4-(6-Amino-9-methyl-9H-purin-2-yl)butan-1-ol

To a solution of 4-(6-amino-9-methyl-9H-purin-2-yl)-but-3-yn-1-ol (1.5 g, 6.88 mmol) in ethanol (30 ml) was added palladium 10% on graphite (1.35 g, 20% in weight). The mixture was stirred for 16 h in autoclave at 50° C. under 4 atm of hydrogen. The catalyst was filtered through a small pad of Celite and the solution obtained was evaporated under reduced pressure, to give a residue that was used for the following reaction without further purification.
Yield 70%.
¹H NMR (DMSO-d₆) δ: 1.49 (m, 2H), 1.70 (m, 2H), 2.55 (t, 2H), 3.39 (m, 2H), 3.67 (s, 3H), 4.34 (bs, 1H), 7.01 (s, 2H), 7.97 (s, 1H).
¹³C NMR (DMSO-d₆) δ: 25.54, 29.68, 32.85, 39.04, 61.09, 117.39, 141.33, 151.04, 156.05, 164.93
MS(ESI) m/e: 222.0 (M+H)⁺

STEP D: 4-(6-Amino-8-bromo-9-methyl-9H-purin-2-yl)butan-1-ol

Bromine (0.4 ml, 6.8 mmol) was added dropwise, at −14° C., to 4-(6-amino-9-methyl-9H-purin-2-yl)butan-1-ol (250 mg, 1.13 mmol) dissolved in a mixture of dioxane (5 ml) and acetate buffer pH 4 (2.5 ml) (obtained by dissolving 4 g of sodium acetate in 100 ml of water and by adjusting to pH 4 with glacial acetic acid). The reaction was stirred at this temperature for 10 minutes and then at RT for 15 minutes. Excess of bromine was eliminated with sodium metabisulphite and the reaction brought to pH 8 by addition of saturated solution of Na₂CO₃. The aqueous phase was extracted with DCM (6×10). The organic phases were dried over anhydrous sodium sulphate and evaporated under reduced pressure, to give a residue that was used for the following reaction without further purification.

STEP E: 4-(6-Amino-9-methyl-8 [1,2,3]triazol-2-yl-9H-purin-2-yl)butan-1-ol (ST4023)

To a solution of 4-(6-amino-8-bromo-9-methyl-9H-purin-2-yl)butan-1-ol (1.4 g, 4.56 mmol) in anhydrous DMF (20 ml) were added Cs2CO3 (5.9 g, 18.24 mmol) and then 1H-1,2,3-triazole (1.2 g, 1.0 ml, 17.2 mmol). The mixture was stirred overnight at 90° C. The solvent was evaporated under reduced pressure to give a residue that was purified by flash chromatography (DCM/MeOH: 93/7).
Yield 30%.
¹H NMR (DMSO-d₆) δ: 1.46 (m, 2H), 1.73 (m, 2H), 2.67 (t, 2H, J=7.5 Hz), 3.38 (m, 2H), 3.76 (s, 3H), 4.38 (bs, 1H), 7.38 (s, 2H), 8,31 (s, 2H).
¹³C NMR (DMSO-d₆) δ: 25.43, 30.65, 32.80, 39.15, 61.04, 114.92, 138.06, 141.42, 151.14, 156.17, 166.17
MS(ESI) m/e: 289 (M+H)⁺

Example 2

4-(6-Amino-9-methyl-8 [1,2,3]triazol-2-yl-9H-purin-2-yl)butan-2-ol (ST3932)

STEP A: 4-(6-Chloro-9-methyl-9H-purin-2-yl)but-3-yn-2-ol

To a solution of 6-chloro-2-iodo-9-methyl-9H -purine (6.8 g, 23.3 mmol), CuI (454 mg, 2.23 mmol) and bis-triphenylphosphine palladium dichloride (811 mg, 1.15 mmol) in dioxane (93 ml) were added triethylamine (4.9 ml, 34.5 mmol) and but-3-yn-2-ol (1.1 ml, 25.63 mmol). The reaction mixture was stirred at RT for 1 h. The volatiles were removed under reduced pressure. Water (50 ml) was added to the dark residue obtained. The aqueous phase was extracted with DCM (3×100 ml). The combined organic phases were dried over anhydrous sodium sulphate and evaporated under reduced pressure. The combined organic phases were dried over anhydrous sodium sulphate and evaporated under reduced pressure. The residue was purified by flash chromatography (DCM/MeOH: 94/6).
Yield 77%.
¹H NMR (CDCl₃) δ: 1.62 (d, 3H, J=6.67 Hz), 3.95 (s, 3H), 4.81 (q, 1H, J=6.64), 8.17 (bs, 1H).
¹³C NMR (CDC₁₃) δ: 23.52, 29.72, 57.31, 81.41, 89.94, 130.59, 144.75, 148.20, 149.21, 152.65.
MS(ESI) m/e: 237-239 (M+H)⁺

STEP B: 4-(6-Amino-9-methyl-9H-purin-2-yl)but-3-yn-2-ol

To a solution of 4-(6-chloro-9-methyl-9H-purin-2-yl) but-3-yn-2-ol (4.8 g, 20.34 mmol) in dioxane (30 ml) was added 30% w/w water solution of ammonia (60 ml). The reaction mixture was stirred overnight in an autoclave at 70° C. The solution was evaporated at atmospheric pressure at 50° C. and then under reduced pressure. The residue was purified by flash chromatography (DCM/MeOH: 97/3).
Yield 78%.
1H NMR (DMSO-d₆) δ: 1.42 (d, 3H, J=6.67 Hz), 3.75 (s, 3H), 4.61 (q, 1H), 5.71 (bs, 1H), 7.42 (bs, 2H) 8.17 (s, 1H).
13C NMR (DMSO-d6) δ: 24.75, 29.89, 56.83, 83.14, 87.63, 130.01, 142.74, 145.65, 150.28, 156.07
MS(ESI) m/e: 218 (M+H)⁺

STEP C: 4-(6-Amino-9-methyl-9H-purin-2-yl)butan-2-ol

4-(6-Amino-9-methyl-9H -purin-2-yl)but-3-yn-2-ol (1.5 g, 6.88 mmol) was placed in an autoclave with ethanol (30 ml) and palladium 10% on graphite (0.350 g, 20% in weight) was added. The mixture was stirred overnight under 4 atm of hydrogen at 50° C. The catalyst was filtered off through Celite and the resulting solution was evaporated under reduced pressure, to give a residue that was used without any further purification.
Yield 70%.
¹H NMR (CD₃OD) δ: 1.21 (d, 3H, J=6.32 Hz), 1.9 (m, 2H), 2.85 (m, 2H), 3.35 (bs, 2H), 3.84 (s, 3H), 3.89 (m, 1H), 8.00 (s, 1H).
¹³C NMR (CD₃OD) δ: 22.01, 28.72, 34.97, 37.72, 66.89, 116.59, 141.54, 150.37, 155.56, 165.42
MS(ESI) m/e: 222 (M+H)+

STEP D: 4-(6-Amino-8-bromo-9-methyl-9H-purin-2-yl)butan-2-ol

Bromine (2.1 ml, 41 mmol) was added dropwise at −14° C. to a solution of 4-(6-amino-9-methyl-9H-purin-2-yl)butan-2-ol (800 mg, 3.60 mmol) in a mixture of Me0H/THF (20 ml, 1/1) and acetate buffer pH=4 (10 ml). The latter was obtained dissolving 4 g of sodium acetate in 100 ml of water and by adjusting to pH 4 through addition of glacial acetic acid. The reaction was stirred at this temperature for 10 minutes and then at RT for 10 minutes. Excess of bromine was quenched by addition of sodium metabisulphite and the reaction was brought to pH 8 by addition of a saturated solution of Na₂CO₃. The organic solvents were evaporated under reduced pressure, to give a solid that was filtered and used without any further purification.
Yield 76%.

STEP E: 4-(6-Amino-9-methyl-8-1,2,3]triazol-2-yl-9H-purin-2-yl) butan-2-ol (ST3932)

To a solution of 4-(6-amino-8-bromo-9-methyl-9H-purin-2-yl)butan-2-ol (1.4 g, 4.56 mmol) in anhydrous DMF (20 ml) were added C_sCO₃(5.9 g, 18.24 mmol) and 1H-1,2,3-triazole (1.2 g, 1.0 ml, 18.24 mmol). The mixture was stirred overnight at 90° C. The solvent was evaporated under reduced pressure to give a residue that was purified by flash chromatography (DCM/MeOH: 93/7).
Yield 27%.
¹H NMR (DMSO-d₆) δ: 1.09 (d, 3H, J=6.2 Hz), 1.78 (m, 2H), 2.72 (m, 2H), 3.66 (m, 1H), 3.77 (s, 3H), 4.45 (bs, 1H), 7.32 (bs, 2H), 8.29 (s, 2H).
¹³C NMR (DMSO-d₆) δ: 24.0, 30.6, 35.9, 38.5, 66.2, 114.9, 138.0, 141.4, 151.2, 156.2, 166.4
MS(ESI) m/e: 289 (M+H)⁺

Example 3

(S)-4-(6-Amino-9-methyl-8-[1,2,3]triazol-2-yl-9H -purin-2-yl) butan-2-ol (ST5748)

This compound was prepared according to the procedure described in Example 2, using (S)-(−)-but-3-yn-2-ol in STEP 1 instead of its racemate. In STEP E, the crude reaction mixture was purified by flash chromatography (DCM/MeOH: 95/5).
HPLC: Rt: 29 mn

Example 4

(R)-4-(6-Amino-9-methyl-8-[1,2,3]triazol-2-yl-9H -purin-2-yl) butan-2-ol (ST5749)

This compound was prepared according to the procedure described in Example 2, using (R)-(−)-but-3-yn-2-ol in STEP 1 instead of its racemate. In STEP E, the crude reaction mixture was first purified by flash chromatography (DCM/MeOH: 95/5).
HPLC: Rt: 26 mn

Example 5

1-(6-Amino-9-methyl-8-[1,2,3]triazol-2-yl-9H -purin-2-yl)butan-l-ol (ST3829)

STEP A: 1-(6-Chloro-9-methyl-9H-purin-2-yl)butan-1-01

To a solution of 6-chloro-2-iodo-9-methyl-9H-purine (3.7 g, 12.6 mmol) in anhydrous THE (48 ml) at −78° C. under an atmosphere of nitrogen was added isopropylmagnesium chloride (8 ml, 15.12 mmol). After 30 minutes butyraldehyde (1.7 ml, 16.38 mmol)was added at −78° C. dropwise. The reaction mixture was stirred at −78° C. for 8 h and then allowed to warm to RT overnight. The reaction was quencend with a saturated solution of NH₄Cl. The aqueous phase was extracted with DCM (three times). The organic phases were dried over anhydrous sodium sulphate and evaporated under reduced pressure. The residue was purified by flash chromatography (gradient DCM/MeOH: 98/2 to DCM/MeOH: 96/4).
Yield 59%.
¹H NMR (CD₃OD) δ: 0.96 (t, 3H, J=7.34), 1.45 (m, 2H), 1.86 (m, 2H), 3.95 (s, 3H), 4.83 (t, 1H, J=6.5), 8.47 (s, 1H).
¹³C NMR (CD₃OD) δ: 12.85, 18.41, 29.22, 38.90, 73.80, 129.13, 147.46, 149.6, 152.53, 166.27.
MS (ESI+): 241-243 (M+H)⁺

STEP B: 1-(6-Amino-9-methyl-9H-purin-2-yl)butan-1-ol

To the solution of 1-(6-chloro-9-methyl-9H-purin-2-yl)butan-1-ol (1.8 g, 7.47 mmol) in dioxane (10 ml) was added 30% w/w water solution of ammonia (20 ml). The reaction mixture was stirred overnight in an autoclave at 70° C. The solution was evaporated at atmospheric pressure at 50° C. and then under reduced pressure. The residue was purified by flash chromatography (DCM/MeOH: 95/5).
Yield 80%.
¹H NMR (DMSO-d₆) δ: 0.93 (t, 3H, J=7.06), 1.40 (m, 2H), 1.78 (m, 2H), 3.77 (s, 3H), 4.48 (m, 1H), 4.84 (d, 1H), 7.31 (s, 2H), 8.12 (s, 1H).
¹³C NMR (DMSO-d₆) δ: 14.95, 19.37, 30.29, 39.99, 73.86, 118.35, 142.33, 151.18, 156.52, 166.43.
MS (ESI+): 222 (M+H)+

STEP C: 1-(6-Amino-8-bromo-9-methyl-9H-purin-2-yl)butan-1-ol

Bromine (3.6 ml, 70.4 mmol) was added dropwise, at −-14° C., to 1-(6-amino-9-methyl-9H-purin-2-yl)butan-1-ol (1700 mg, 7.69 mmol) dissolved in a mixture of MeOH (20 ml), THF (20 ml) and acetate buffer pH 4 (20 ml) (obtained by dissolving 4 g of sodium acetate in 100 ml of water and by adjusting pH 4 with glacial acetic acid). The reaction was stirred at this temperature for 15 minutes and then at RT for 10 minutes. Excess of bromine was eliminated with sodium metabisulphite and the reaction brought to pH 8 by addition of saturated solution of Na₂CO₃. The organic solvents were evaporated under reduced pressure, to give a solid that was filtered and used for the following reaction without further purification.
Yield 82%.

STEP D: 1-(6-Amino-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-2-yl)butan-1-ol (ST3829)

To the solution of 1-(6-amino-8-bromo-9-methyl-9H-purin-2-yl)-butan-1-ol (1.4 g, 4.56 mmol) in anhydrous DMF (20 ml) were added C_sCO₃(5.9 g, 18.24 mmol) and then 1H-1,2,3-triazole (1.2 g, 1.0 m1,18.24 mmol). The mixture was stirred overnight at 90° C. The solvent was evaporated under reduced pressure to give a residue that was purified by flash chromatography (DCM/MeOH: 93/7).
Yield 30%.
¹H NMR (DMSO-d₆) δ: 0.92 (t, 3H, J=7.18), 1.40 (q, 2H, J=8.2), 1.75 (m, 2H), 3.86 (s, 3H), 4.50 (m, 1H), 4.88 (d, 1H), 7.58 (bs, 1H), 8.37 (s, 2H).
¹³C NMR (DMSO-d₆) δ: 14.94, 19.37, 31.34, 39.88, 74.06, 115.90, 138.63, 142.27, 151.42, 156.64, 167.72.
MS (ESI+): 289(M+H)⁺

Example 6

1-(6-Amino-9-methyl-8-[1,2,3]triazol-2-14-9H-purin-2-1/1)-butan-1-one ST4208

MnO₂(439mg, 5.04 mmol) was added to a solution of 1-(6-amino-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-2-yl)butan-1-ol (51mg, 0.2mmol) in DCM (4 ml) at RT. The resulting heterogeneous solution was stirred overnight. After filtration over a celite pad, the solvent was removed under reduced pressure to afford the desired product as a white powder.
Yield 40%.
¹H NMR (DMSO-d₆) δ: 8.4 (s, 2H), 7.7 (bs, 2H), 3.9 (s, 3H), 3.14 (t, 2H), 1.66 (m, 2H), 0.95 (t, 3H)
ESI-MS (m/z): 287.1(M+H)⁺

Example 7

4-(6-Amino-9-methyl-8-[1,2,3]triazol-2-yl -9H-purin-2-yl)-butan-2-one ST4206

Molecular sieves 4 Å(100 mg) and PCC (59 mg, 0.273 mmol) at 0° C. were added to a solution of 4-(6-amino-9-methyl-8[1,2,3]triazol-2-yl-9H-purin-2-yl)-butan-2-ol (25 mg, 0.086 mmol) in DCM (1.2 ml). The mixture was stirred at RT for 1 h and then diluted with Et₂O at 0° C. and stirred for 30 minutes. The resulting suspension was filtered through a celite pad. The filtrate was concentrated in vacuo and the residue was purified by silica gel column chromatography (DCM to DCM/MeOH: 95/5) to afford a white powder.
Yield 37%.
¹H NMR (CD₃CN) δ: 8.1 (s, 2H), 5.9 (bs, 2H), 3.8 (s, 3H), 3.07 (t, 2H), 2.9 (t, 2H), 2.2 (s, 3H).
ESI-MS (m/z): 287.1 (M+H)⁺
In alternative, 4-(6-amino-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-2-yl)-butan-2-one can be prepared from an advanced intermediate obtained by a process involving Method B as above mentioned and as described underneath.

Preparation 1

4-(6-Amino-9-methyl-8-[1,2,3]triazol-2-yl-9H -purin-2-yl)-butan-2-one (ST4206)

STEP A: Dibenzyl-{9-methyl-2-[2-(2,5,5-trimethyl-[1,3]dioxan-2-yl)-ethyl]-9H-purin-6-yl}-amine

i) 1,2-dibromoethane (770 μl, 8.9 mmol) was added to a suspension of Mg (3.1 g, 127.5 mmol) in THF (75 ml) in inert atmosphere (Ar). Then, a solution of 2-(2-bromoethyl)-2,5,5-trimethyl-1,3-dioxane (8.0 ml, 42.5 mmol) and 1,2-dibromoethane (3.08 ml, 36 mmol) in THF (75 ml) was added, and after the exothermic reaction was completed, the resulting reaction mixture was heated to 50° C. for 1 h.
ii) Fe(acac)₃(315 mg, 0.89 mmol) was added to a solution of dibenzyl-(2-chloro-9-methyl-9H-purin-6-yl)-amine (3.24 g, 8.9 mmol) in THF (115 ml) and NMP (28. 5 ml) and the resulting reaction mixture was stirred at RT for 30 min. 140 ml of the freshly prepared reagent obtained from STEP A (i) were added to the reaction mixture and the stirring was maintained for 1 h. The solvent was removed under reduced pressure, and the crude reaction mixture was poured into water and extracted by means of AcOEt. The combined organic phases were washed with brine and dried with Na.₂SO₄. After removal of the solvent under reduced pressure, the desired adduct was obtained quantitatively as a brown oil.
¹H NMR (CDCl₃) δ: 0.85 (s, 3H), 1.00 (s, 3H), 1.30 (s, 3H), 1.89-2.00 (m, 2H), 2.85-2.91 (m, 2H), 3.47-3.61 (m, 4H), 3.80 (s, 3H), 4.91(brs, 2H), 5.40(brs, 2H), 7.2-7.4 (m, 10H), 7.66 (s, 1H).
ESI-MS (m/z): 486 (M+H)⁺

STEP B: Dibenzyl-{8-bromo-9-methyl-2-[2-(2,5,5-trimethyl- 8 1,31]dioxan-2-yl)-ethyl]-9H-purin-6-yl}amine

Bromine (0.89 ml, 17.5 mmol) was added dropwise at 0° C. to a solution of dibenzyl-{9-methyl-2-[2-(2,5,5-trimethyl-[1,3]dioxan-2-yl)-ethyl]-9H-purin-6-yl}amine (1.7 g, 3.50 mmol) in 20 ml of a mixture of MeOH/THF (1/1) and acetate buffer pH=4 (10 ml). The latter was obtained dissolving 4 g of sodium acetate in 100 ml of water and by adjusting to pH 4 through addition of glacial acetic acid. The reaction was stirred at RT for two hours. Excess of bromine was quenched by addition of sodium metabisulphite and the reaction was brought to pH 8 by addition of a saturated solution of Na₂CO₃. The organic solvents were evaporated under reduced pressure, to give a solid that was filtered and used without any further purification in the next step.
¹H NMR (CDCl₃) δ: 0.85 (s, 3H), 1.00 (s, 3H), 1.30 (s, 3H), 1.89-2.00 (m, 2H), 2.82-2.89 (m, 2H), 3.47-3.61 (m, 4H), 3.75 (s, 3H), 4.91(bs, 2H), 5.40(bs, 2H), 7.20-7.40 (m, 10H).
ESI-MS (m/z): 564-566 (M+H)⁺
STEP C: Dibenzyl-{9-methyl-8-[1,2,3]triazol-2-yl-2-[2-(2,5,5-trimethyl-[1,3]dioxan-2-yl)-ethyl]-9H-purin-6-yl}-amine
To a solution of dibenzyl-{8-bromo-9-methyl-2-[2-(2,5,5-trimethyl-[1,3]dioxan-2-yl)-ethyl]-9H-purin-6-yl}amine (1.9 g, 3.50 mmol) in anhydrous DMF (20 ml) were added K₂CO₃(0.72 g, 5.2 mmol) followed by 1H-1,2,3-triazole (362 mg, 5.2 mmol). The mixture was stirred overnight at 100° C. The solvent was evaporated under reduced pressure to give a residue that was purified by flash chromatography (DCM/MeOH: 93/7).
Yield 30%.
¹H NMR (CDCl3) δ: 0.85 (s, 3H), 1.00 (s, 3H), 1.30 (s, 3H), 1.89-2.00 (m, 2H), 2.79-2.83 (m, 2H), 3.47-3.61 (m, 4H), 3.90 (s, 3H), 4.91(brs, 2H), 5.40 (bs, 2H), 7.2-7.4 (m, 10H), 8.00 (s, 21-1).
MS(ESI) m/e: 553 (M+H)⁺

STEP D: 4-(6-Amino-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-2-yl)-butan-2-one (ST4206)

The intermediate obtained form STEP C, was deprotected using standard TfOH conditions, which after chromatography on silica gel allowed the obtention of the desired adduct quantitatively.
¹H NMR (CD3CN) δ: 8.10 (s, 2H), 5.90 (bs, 2H), 3.80 (s, 3H), 3.07 (t, 2H), 2.90 (t, 2H), 2.20 (s, 3H).
ESI-MS (m/z): 287 (M+H)⁺
In alternative, 4-(6-amino-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-2-yl)-butan-2-one can be prepared from an advanced intermediate obtained by a process involving Method E as above mentioned and as described underneath.

Preparation 2

Hermann catalyst (8 mg, 0.008 mmol, 0.08 eq), Bu₄NBr (8 mg, 0.025 mmol, 0.25 eq), NaOAc (9 mg, 0.11 mmol, 1.1 eq) and 3-buten-2-ol (13μl, 0.15 mmol, 1.5 eq) were added to a solution of (2-chloro-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-yl)-bis-(4-methoxy-benzyl)-amine (49 mg, 0.10 mmol) in NMP (1 ml). The resulting reaction mixture was heated to 100° C. for 16 h and further Hermann catalyst, Bu₄NBr, and NaOAc were added in the same proportions together with further 3 eq of 3-buten-2-ol. The stirring was continued for 22 h at 140° C. before cooling to RT. The resulting crude suspension was diluted with AcOEt and the solid was filtered off. The organic phase was washed with H₂O and then dried over Na₂SO₄. Removal of the solvent under vacuo and purification through preparative thin layer chromatography allowed the obtention as a white solid of the desired 4-{6-[bis-(4-methoxy-benzyl)-amino]-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-2-yl}-butan-2-one.
Yield 42%.
¹H NMR (CDCl₃) δ: 2.12 (s, 3H), 2.94 (t, 2H), 3.16 (t, 2H), 3.78 (s, 6H), 3.94 (s, 3H), 4.85 (bs, 2H), 5.39(bs, 2H), 6.82 (d, 4H), 7.18 (d, 4H), 7.94 (s, 2H).

Biology

The compounds of the present invention were tested in a competition binding assay for their ability to inhibit A_2areceptor.

Example 8

A_2aReceptor Inhibition

Method
HEK293 Cell Culture and Membrane Preparation
HEK293 cells, stably expressing the human adenosine A_2a, receptor gene (PerkinElmer, Boston, Mass., USA, cat. RBHA2AC), were grown in Falcon flasks in DMEM (Cambrex, Verviers, Belgium) supplemented with 10% FBS (Cambrex), 1 mmol/l sodium pyruvate (Sigma-Aldrich, Saint Louis, Mo., USA), 0.4 mg/ml G418 (Sigma-Aldrich) at 37° C. in a 5% CO₂atmosphere. For radioligand binding experiments, the cells were collected at 80% of confluence, in 5 mmol/l Tris-HCl (Sigma-Aldrich), pH 7.4, containing 2 mmol/l EDTA, counted, washed in PBS (Cambrex), resuspended in incubation buffer A containing 50 mmol/l Tris-HCl, pH 7.4,10 mmol/l MgCl₂(Sigma-Aldrich) and homogenized using an Ultra Turrax T25. The membranes were centrifuged and homogenized once again and the final pellet was stored at −80° C. until use. Prior to the competition binding assay, the pellet was resuspended in buffer A at the desired protein concentration and membrane suspension was incubated with 2 U/ml adenosine deaminase (ADA, Sigma-Aldrich) for 30 min at 37 ° C. to remove endogenous adenosine.

Protein Concentration and Competition Binding Assay

The protein concentration of membrane suspension was determined using the Bradford method (Pierce, Rockford, Ill., USA) with bovine albumin as standard. Competition binding experiments were performed by incubating membranes (5-10 μg of protein/sample) with a single concentration of the A_2aantagonist [³H]ZM241385 (Biotrend, Cologne, Germany) (2 nmol/l), in the presence of various concentrations (ranging from 10⁻⁵to 10⁻¹¹mol/l) of test and reference compounds in 96-well filter plates (MultiScreen system, cat. MAFBNOB10, Millipore, Billerica, Mass., USA) for one h at 4 ° C. in a total volume of 200μl/well of appropriate buffer (50 mmol/l Tris-HCl, pH 7.4, 10 mmol/l MgCl₂). Nonspecific binding was determined in the presence of 10 μmol/l cold ZM241385 (Tocris, Ellisville, Mo., USA). At the end of incubation, bound and free radioligands were separated by filtering the 96-well filter plates using a Millipore filtration apparatus (MultiScreenHTS vacuum manifold). Filter plates were then washed several times with ice-cold buffer (50 mmol/l Tris-HCl, pH 7.4) and filter-bound radioactivity measured using a MicroBeta counter (PerkinElmer) after addition of 30 μl/well of OptiPhase SuperMix scintillation cocktail (PerkinElmer). Four experiments were performed in triplicate by JANUS® automated workstation (Perkin Elmer).
Data were analyzed by nonlinear regression analysis with GraphPad PRISM commercial software and expressed as IC₅₀, defined as the concentration of compounds that inhibits 50% of [³H]ZM241385 binding. Inhibitory binding constant (Ki) values were calculated from IC₅₀values according to the Cheng and Prusoff equation Ki=IC₅₀/(1+[C]/K_d), where [C] is the concentration of the radioligand and K_dits dissociation constant.

Results

All tested compounds proved to be highly active in binding A2A receptor assay (table 1).

	TABLE 1

		A_2A
	Examples	Ki nM

	1	53
	2	8
	3	19
	4	8
	5	22
	6	19
	7	12

Example 9

A1 receptor inhibition
Method
Competition binding experiments have been performed incubating membranes from CHO-K1 cells stably transfected with the human adenosine Al receptor (cat. ES-010-M400UA, Perkin Elmer, Boston, Mass., USA) (5-10 μg of protein/sample) with a single concentration of [3H]DPCPX (1.7 nmol/l) (Perkin Elmer), in the presence of various concentrations (ranging from 10⁻⁵to 10 ⁻¹⁰M) of cold DPCPX, ST4206 and ST4208 in 96-well filter plates (MultiScreen system, cat #MAFBNOB10, Millipore, Billerica, Mass., USA) for 60 min at 25° C. in a total volume of 200 μL/well of 25 mmol/l Hepes, 5 mmol/l MgCl₂, 1 mmol/l CaCl₂, 100 mmol/L NaCl, pH 7.4 (all from Sigma-Aldrich). Non-specific binding has been determined in the presence of 250 μmol/l of cold DPCPX (8-cyclopentyl-1,3-dipropylxanthine, Sigma-Aldrich). At the end of incubation, bound and free radioligands have been separated by filtering the 96-well filter plates using a Millipore filtration apparatus (MultiscreenHTS vacuum manifold). Filter plates have been washed several times with ice-cold buffer (50 mmol/l Tris-HCl, pH 7.4) and filter-bound radioactivity measured using a MicroBeta counter (PerkinElmer) after addition of 30 μL/well of OptiPhase SuperMix scintillation cocktail (PerkinElmer).
Data have been analyzed using nonlinear regression with GraphPad PRISM commercial software. Data will be expressed as test compound concentration causing a half maximal inhibition of control values (IC₅₀). Inhibitory binding constant (Ki) values will be calculated from IC₅₀values, according to the Cheng and Prusoff equation K_i=IC₅₀/(1+[C]/K_d), where [C] is the concentration of the radioligand and K_dits dissociation constant.

Results

Tested compounds bound A₁adenosine receptors with the Ki values reported in Table 2.

	TABLE 2

		A₁
	Examples	Ki nM

	1	51
	2	27
	5	120
	6	216
	7	197

Example 10

cAMP Inhibition
The compounds of the present invention were tested to assess their capacity to inhibit cAMP accumulation induced by the A_2Aagonist 5′-N-ethylcarboxamidoadenosine (NECA).

Methods

cAMP quantitative determination was performed with an enzyme immunoassay system (cat. RPN2255, Amersham Biosciences) according to manufacturer's instructions. HEK 293 cells, stably expressing the human adenosine A_2a, receptor gene (PerkinElmer, Boston, Mass., USA, cat. RBHA2AC), were grown in Falcon flasks in DMEM (Cambrex, Verviers, Belgium) supplemented with 10% FBS (Cambrex), 1 mmol/1 sodium pyruvate (Sigma-Aldrich, St. Louis, Mo., USA), and 0.4 mg/ml G418 (Sigma-Aldrich) at 37° C. in a 5% CO₂atmosphere. Cells were plated on 96-well dishes at a concentration of 10³cells/well 48 hours before test compound exposure. Before cell stimulation with the compounds, cells were treated for 10 min at 37° C. with 0.5 mmol/l of the phosphodiesterase inhibitor Ro 20-1724 (Sigma-Aldrich) and with 2 U/ml of adenosine deaminase (ADA, Sigma-Aldrich). Medium was then changed with fresh medium containing scalar concentrations of test compounds (10⁻¹⁰-10⁻⁴mol/l) at 37° C. and, after 10 min, 100 nmol/l NECA was added cAMP was extracted 20 min after and quantified.
Data were analyzed by nonlinear regression analysis with GraphPad PRISM commercial software. Test compound concentrations causing a half maximal inhibition of control values (IC₅₀calculated by GraphPad Prism software) was reported (mean±SEM of four independent experiments).

Results

All compounds resulted efficacious at inhibiting agonist-induced cAMP accumulation (table 3) and behaved as expected for A_2areceptor antagonists.

	TABLE 3

		cAMP
	Examples	IC₅₀μM

	1	2.12
	2	0.45
	3	0.26
	4	0.42
	5	2.32
	6	2.92
	7	0.99

Example 11

In order to evaluate the selectivity profile of the compounds of the present invention, three of them (ST3829, ST3932 and ST4023) were also characterized for their affinity toward a battery of 51 different receptors. The majority of the 51 assays were human recombinant receptors of the following types: adenosine, adrenergic, cannabinoid, dopamine, GABA, histamine, melatonin, muscarinic, prostanoid and serotonin receptors belonging to non peptide receptors family; angiotensin-II, bradychinin, chemokines, cholecistokinin, endothelin, galanin, melacortin, neurokinin, neuropeptide Y, neurotensin, opioid and opioid like, somatostatin, vasoactive intestinal peptide and vasopressin receptors belonging to peptide receptors family; Ca²⁺ channel, K⁺ channel and Nachannel belonging to the ion channel family and dopamine, norepinephrine and serotonin belonging to the amine transporters receptors family. These three compounds were tested at a concentration of 10μM. Interestingly, none of them demonstrated any substantial affinity toward any of the above-mentioned receptors.

Example 12

Haloperidol-Induced Catalepsy Mice Model

ST3829, ST3932 and ST4023 were tested to assess their capacity to antagonize haloperidol-induced catalepsy in mice.

Methods

Haloperidol (2 mg/kg) was injected i.p. to CD1 mice 2.5 h before oral administration of ST3932 or ST4206. The latter were administered at doses of 10, 20 or 40 mg/kg.
Then, each CD1 mouse was gently placed by its forepaws on a wire at a height of 4.5 cm. Catalepsy was measured as the time (expressed in seconds) necessary for the animal to step down with at least one forepaw, with an end point of 60 seconds, time after which the mouse was gently removed from the wire. Then, catalepsy was scored every 60 min for seven h.

Data Evaluation

All data were expressed both as individual and mean values, plus or minus standard error (Mean±SEM) of catalepsy time in seconds. Statistical analysis was performed using sigma stat program. After calculation of AUC throughout 7 hours, the one-way ANOVA followed by Dunnett's test were used. Basal time was not considered statistically because this time-point was only used to check that catalepsy was successfully induced in all animals.

Results

Both ST3932 and ST4206 significantly antagonized haloperidol-induced catalepsy in a dose-dependent manner (FIGS. 1 and 2).

Example 13

Enhancement of L-DOPA Antiparkinsonian Activity

Rats (Sprague Dawley) under chloral hydrate (400 mg/kg) anaesthesia were placed in a Kopf stereotaxic apparatus. Through a stainless steel cannula, 6-OHDA was injected at a rate of 1 μl/min into the left medial forebrain bundle at coordinates A=−2.2, L=+1.5 and V=−7.8, according to the Pellegrino atlas. All rats, including shams, were treated with desipramine (10 mg/kg) 10 min before anaesthesia to prevent damage to noradrenergic neurons.
Two weeks after the 6-OHDA injection, all animals were tested for their contra lateral rotation capacity in response to 30 mg/kg i.p. benserazide followed by 50 mg/kg i.p. of L-Dopa 30 min later. Rats not showing at least 200 contra lateral rotations within the 3 h testing period were eliminated from the study. One week after this test, selected animals were randomized to be enrolled in three studies. Each study involved seven groups of eight animals.
Tested compounds (ST3829, ST3932 and ST4206) were dissolved in a solution containing 10% sucrose and 0.3% Tween 80 in sterile water in order to obtain three different dosage forms (i.e., 10, 20 and 40 mg/kg).


	Group 1	Tested compound 10 mg/kg
	Group
2	Tested compound 20 mg/kg
	Group
3	Tested compound 40 mg/kg
	Group
4	6 mg benserazide + 3 mg L-DOPA
	Group
5	Tested compound 10 mg/kg and 6 mg
		benserazide + 3 mg L-DOPA
	Group
6	Tested compound 20 mg/kg and 6 mg
		benserazide + 3 mg L-DOPA
	Group
7	Tested compound 40 mg/kg and 6 mg
		benserazide + 3 mg L-DOPA

In groups 5, 6 and 7 benserazide was administered first, followed by the tested compound 25 min after and finally by L-DOPA 5 min later.

Results

In the 6-OHDA rat model of Parkinson's disease, adenosine A2a receptor antagonists increase turning behaviour induced by L-Dopa showing antiparkinsonian effects. In this study it was shown that ST3932 and ST4206, administered to rats with a threshold dose of L-Dopa, increased the contralateral turning behaviour induced by L-Dopa displaying a marked antiparkinsonian activity.

Claims

1-15. (canceled)

16. A compound having the general formula I

R¹is C₁-C₆linear or branched alkyl;

R²is a group of formula:

R⁹—(CHR⁸)_p—(CR⁶R⁷)_m—(CR⁴R⁵)_n;

R⁴, R⁶and R⁸are independently H, hydroxyl or ═O with the meaning of carbonyl;

R⁵, R⁷and R⁹are independently H or are absent;

m, n and p are independently an integer comprised between 0 and 2;

m+n+p≧4;

R³is NH₂or NHR¹⁰;

R¹⁰is linear or branched C₁-C₆alkyl; linear or branched C₁-C₆hydroxyalkyl; linear or branched (C₁-C₃)alkoxy(C₁-C₆)alkyl; amino(C₁-C₆)alkyl, where the amino group is optionally substituted with one or two linear or branched C₁-C₃alkyl groups; C₆-C₁₄aryl; or C₆-C₁₄aryl(C₁-C₆)alkyl, wherein said C₆-C₁₄aryl group is optionally substituted by one or more substituents, which are the same or different, selected from the group consisting of halogen; hydroxyl; linear or branched, saturated or unsaturated C₁-C₆alkoxy; and amino, where the amino group is optionally substituted with one or two linear or branched C₁-C₆alkyl groups;

or an optically active form, or pharmaceutically acceptable salt thereof;

with the proviso that R⁴, R⁶and R⁸are not all H at the same time.

17. The compound according to claim 16 wherein n=2, m=1 and p≧1.

18. The compound according to claim 16, wherein R⁶is OH or =0 with the meaning of carbonyl.

19. The compound according to claim 16 wherein n=1 and R⁴is OH or ═O with the meaning of carbonyl.

20. The compound according to claim 16 which is 4-(6-amino-9-methyl-8 [1,2,3]triazol-2-yl-9H-purin-2-yl)butan-1-ol, 1-(6-amino-9-methyl-8 [1,2,3 ]triazol-2-yl-9H-purin-2-yl)butan-1-ol, 4-(6-amino-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-2-yl)-butan-2-one, 4-(6-amino-9-methyl-8[1,2,3]triazol-2-yl-9H-purin-2-yl) butan-2-ol, or 1-(6-amino-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-2-yl)-butan-1-one or a pharmaceutically acceptable salt thereof.

21. The compound of claim 16 which is 4-(6-amino-9-methyl-8[1,2,3]triazol-2-yl-9H-purin-2-yl) butan-2-one or a pharmaceutically acceptable salt thereof.

22. A pharmaceutical composition comprising at least one compound according to claim 16 or an optically active form, or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable vehicle and/or excipient.

23. The pharmaceutical composition according to claim 22 wherein the compound is 4-(6-amino-9-methyl-8[1,2,3]triazol-2-yl-9H-purin-2-yl)butan-1-ol, 1-(6-amino-9-methyl-8[1,2,3]triazol-2-yl-9H-purin-2-yl)butan-1-ol, 4-(6-amino-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-2-yl)-butan-2-one, 4-(6-amino-9-methyl-8[1,2,3]triazol-2-yl-9H-purin-2-yl)butan-2-ol, or 1-(6-amino-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-2-yl)-butan-1-one or a pharmaceutically acceptable salt thereof.

24. The pharmaceutical composition according to claim 22 which further comprises L-DOPA.

25. A process for preparing a pharmaceutical composition comprising mixing at least one compound according to claim 16 or an optically active form, or a pharmaceutically acceptable salt thereof with at least one pharmaceutically acceptable vehicle and/or excipient.

26. A method for treating a pathological state for which the modulation of A_2Aactivity would result at improving the health of a patient which comprises administering an effective amount of compound according to claim 16 or an optically active form, or a pharmaceutically acceptable salt thereof to a patient in need thereof.

27. The method according to claims 26 wherein the pathological state is a motor disorder.

28. The method according to claim 27, wherein said motor disorder is Parkinson's disease, Alzheimer's disease, Huntington's disease, Wilson's disease or Hallervorden-Spatz disease.

29. The method according to claim 26 wherein said pathological state is cerebral ischaemia optionally associated with neurodegenerative processes.

30. A method for treating Parkinson's disease which comprises administering an effective amount of the pharmaceutical composition according to claim 24 to a patient in need thereof.

31. A process for synthesizing a compound of claim 16, which comprises reacting a compound of the formula II

wherein

R¹is C₁-C₆linear or branched alkyl;

_R11 is N(_R ¹³)₂;

R¹³is benzyl, p-(Me0)-benzyl, p-(C1)-benzyl or p-(Br)-benzyl;

R¹²is Cl;

with a compound of formula IX

wherein

R¹⁴and R¹⁵are at each occurrence independently H or OH;

V is 2 or 3;

in the presence of Hermann's catalyst and sodium acetate in a polar solvent.